We are excited to share that our partner, Everest Medicines, has dosed the first patient in China. Their team continues to integrate seamlessly with ours to drive forward our global Phase 2b clinical trial evaluating zetomipzomib in adults living with LN. https://lnkd.in/gJu83GfZ
Kezar Life Sciences
Biotechnology Research
South San Francisco, California 4,927 followers
Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders
About us
We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.
- Website
-
https://kezarlifesciences.com/
External link for Kezar Life Sciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2015
- Specialties
- Biotechnology, Autoimmune Disease, Immunology, Oncology, Drug Discovery, and Drug Development
Locations
-
Primary
Get directions
4000 Shoreline Ct
Suite 300
South San Francisco, California 94080, US
Employees at Kezar Life Sciences
Updates
-
Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at https://lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib #LupusNephritis
-
-
Kezar Life Sciences reposted this
Section Chief of Hepatology/Associate Director of Organ Transplantation at Rush University Medical Center
Let’s aim for a steroid-free future to treat #autoimmunehepatitis! Read about treatments in development for #AIH in @HepCommJournal [https://lnkd.in/gGd4QDFX]. #openacess https://lnkd.in/gjnJ8wEy
-
Tomorrow, Kezar’s CEO Chris Kirk will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: https://lnkd.in/eQbXMpBN. #Jefferies #Healthcare #LupusNephritis
-
-
Lupus nephritis is a frequent and moderate-to-severe complication of lupus affecting the kidneys. Learn about Kezar’s selective immunoproteasome inhibitor zetomipzomib being evaluated for those living with lupus nephritis: https://lnkd.in/gtxDfybE. #LupusAwarenessMonth
-
-
Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: https://lnkd.in/gZn2_Gdu #Jefferies #Healthcare #Zetomipzomib
-
-
Learn more about the PALIZADE trial by visiting https://lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib
-
-
From our families to yours, Happy Mother's Day. #mothersday